Regeneron Pharmaceuticals shares are trading lower after the FDA declined to approve a higher-dose version of EYLEA. Multiple analysts lowered their price targets on the stock.
Portfolio Pulse from Benzinga Newsdesk
Regeneron Pharmaceuticals' shares are trading lower after the FDA declined to approve a higher-dose version of EYLEA. This has led to multiple analysts lowering their price targets on the stock.
June 28, 2023 | 3:06 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Regeneron's stock price is expected to decrease in the short term due to the FDA's rejection of a higher-dose EYLEA and subsequent lowering of price targets by analysts.
The FDA's rejection of a higher-dose version of EYLEA is a significant setback for Regeneron, as it limits the potential market and revenue for the drug. This has led to a decrease in the company's stock price and analysts lowering their price targets, indicating a negative outlook for the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100